Brookline Cap M Estimates iBio’s Q3 Earnings (NYSE:IBIO)

iBio, Inc. (NYSE:IBIO) – Investment analysts at Brookline Cap M lifted their Q3 2026 EPS estimates for iBio in a research report issued to clients and investors on Wednesday, February 11th. Brookline Cap M analyst K. Dolliver now anticipates that the company will post earnings per share of ($0.07) for the quarter, up from their prior forecast of ($0.08). The consensus estimate for iBio’s current full-year earnings is ($1.74) per share. Brookline Cap M also issued estimates for iBio’s Q4 2026 earnings at ($0.08) EPS, FY2026 earnings at ($0.34) EPS, Q1 2027 earnings at ($0.08) EPS, Q2 2027 earnings at ($0.08) EPS, Q3 2027 earnings at ($0.08) EPS, Q4 2027 earnings at ($0.08) EPS and FY2027 earnings at ($0.32) EPS.

Several other research analysts have also issued reports on IBIO. Chardan Capital reiterated a “buy” rating and issued a $5.00 target price on shares of iBio in a research report on Thursday. Oppenheimer reaffirmed an “outperform” rating on shares of iBio in a research note on Wednesday, October 29th. Three analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $4.00.

iBio Price Performance

Shares of NYSE:IBIO opened at $2.22 on Monday. The company’s fifty day moving average price is $2.15 and its 200-day moving average price is $1.38. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.76 and a quick ratio of 1.76. The firm has a market capitalization of $76.69 million, a price-to-earnings ratio of -2.22 and a beta of 1.26. iBio has a one year low of $0.56 and a one year high of $6.89.

Institutional Investors Weigh In On iBio

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Cubist Systematic Strategies LLC bought a new position in shares of iBio during the first quarter valued at approximately $224,000. Ameriprise Financial Inc. purchased a new position in iBio during the 3rd quarter valued at $399,000. Boothbay Fund Management LLC raised its holdings in iBio by 10.9% in the 3rd quarter. Boothbay Fund Management LLC now owns 176,862 shares of the company’s stock worth $146,000 after purchasing an additional 17,414 shares in the last quarter. Citadel Advisors LLC bought a new position in iBio in the 3rd quarter worth $109,000. Finally, Susquehanna International Group LLP purchased a new stake in shares of iBio in the 3rd quarter worth about $37,000. 7.90% of the stock is currently owned by institutional investors.

iBio Company Profile

iBio, Inc (NYSE: IBIO) is a biotechnology company that develops and manufactures plant-based biologics, including vaccines and therapeutic proteins. Leveraging proprietary technology derived from Nicotiana benthamiana, a relative of tobacco, iBio applies a molecular farming approach to produce complex proteins more rapidly and with greater scalability than traditional cell-culture methods. The company’s core expertise lies in its ability to design, express and purify recombinant proteins for both research and commercial applications.

Central to iBio’s operations is the iBio CDM™ (cGMP-Direct Manufacture) platform, an integrated system that enables end-to-end development and production of biologics.